Logo image of RHE

REGIONAL HEALTH PROPERTIES (RHE) Stock Fundamental Analysis

NYSEARCA:RHE - NYSE Arca - US75903M3097 - Common Stock - Currency: USD

2.7741  +0.09 (+3.51%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RHE. RHE was compared to 105 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of RHE have multiple concerns. RHE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RHE has reported negative net income.
In the past year RHE had a positive cash flow from operations.
In the past 5 years RHE reported 4 times negative net income.
RHE had a positive operating cash flow in 4 of the past 5 years.
RHE Yearly Net Income VS EBIT VS OCF VS FCFRHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

1.2 Ratios

RHE has a worse Return On Assets (-4.81%) than 62.96% of its industry peers.
Industry RankSector Rank
ROA -4.81%
ROE N/A
ROIC N/A
ROA(3y)10.26%
ROA(5y)3.75%
ROE(3y)6943.44%
ROE(5y)4142.66%
ROIC(3y)N/A
ROIC(5y)N/A
RHE Yearly ROA, ROE, ROICRHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K 20K

1.3 Margins

RHE has a Gross Margin of 49.69%. This is in the better half of the industry: RHE outperforms 76.85% of its industry peers.
RHE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RHE Yearly Profit, Operating, Gross MarginsRHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200

More info and screens

0

2. Health

2.1 Basic Checks

RHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RHE has been increased compared to 1 year ago.
Compared to 5 years ago, RHE has more shares outstanding
The debt/assets ratio for RHE is higher compared to a year ago.
RHE Yearly Shares OutstandingRHE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
RHE Yearly Total Debt VS Total AssetsRHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

RHE has an Altman-Z score of -1.80. This is a bad value and indicates that RHE is not financially healthy and even has some risk of bankruptcy.
RHE has a worse Altman-Z score (-1.80) than 82.41% of its industry peers.
RHE has a debt to FCF ratio of 60.13. This is a negative value and a sign of low solvency as RHE would need 60.13 years to pay back of all of its debts.
RHE has a Debt to FCF ratio (60.13) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 60.13
Altman-Z -1.8
ROIC/WACCN/A
WACC5.19%
RHE Yearly LT Debt VS Equity VS FCFRHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M

2.3 Liquidity

RHE has a Current Ratio of 0.29. This is a bad value and indicates that RHE is not financially healthy enough and could expect problems in meeting its short term obligations.
RHE has a worse Current ratio (0.29) than 93.52% of its industry peers.
A Quick Ratio of 0.29 indicates that RHE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.29, RHE is doing worse than 93.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
RHE Yearly Current Assets VS Current LiabilitesRHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

RHE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.34%.
RHE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.56%.
RHE shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.88% yearly.
EPS 1Y (TTM)-108.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.19%
Revenue 1Y (TTM)-24.56%
Revenue growth 3Y-0.79%
Revenue growth 5Y-4.88%
Sales Q2Q%2.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RHE Yearly Revenue VS EstimatesRHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RHE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RHE Price Earnings VS Forward Price EarningsRHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RHE is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, RHE is valued cheaply inside the industry as 95.37% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.77
EV/EBITDA 28.41
RHE Per share dataRHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RHE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGIONAL HEALTH PROPERTIES

NYSEARCA:RHE (2/3/2025, 8:04:01 PM)

2.7741

+0.09 (+3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2024-11-13
Earnings (Next)03-31 2025-03-31
Inst Owners2.13%
Inst Owner Change0%
Ins Owners14.05%
Ins Owner Change0%
Market Cap5.22M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend3.45
Dividend Growth(5Y)90.1%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF 6.77
P/OCF 4.2
P/B N/A
P/tB N/A
EV/EBITDA 28.41
EPS(TTM)-1.55
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.41
FCFY14.76%
OCF(TTM)0.66
OCFY23.81%
SpS9.15
BVpS-1.27
TBVpS-3.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.81%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.69%
FCFM 4.48%
ROA(3y)10.26%
ROA(5y)3.75%
ROE(3y)6943.44%
ROE(5y)4142.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 60.13
Debt/EBITDA 25.78
Cap/Depr 23.41%
Cap/Sales 2.74%
Interest Coverage N/A
Cash Conversion 69.15%
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -1.8
F-Score4
WACC5.19%
ROIC/WACCN/A
Cap/Depr(3y)19.64%
Cap/Depr(5y)15.23%
Cap/Sales(3y)2.27%
Cap/Sales(5y)1.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-24.56%
Revenue growth 3Y-0.79%
Revenue growth 5Y-4.88%
Sales Q2Q%2.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y79.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y148.86%
FCF growth 3Y48.26%
FCF growth 5Y22.22%
OCF growth 1Y189.42%
OCF growth 3Y42.05%
OCF growth 5Y22.46%